Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $172.0 million.

  • UroGen Pharma's Cash & Equivalents fell 27.92% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year decrease of 27.92%. This contributed to the annual value of $172.0 million for FY2024, which is 81.04% up from last year.
  • Per UroGen Pharma's latest filing, its Cash & Equivalents stood at $172.0 million for FY2024, which was up 81.04% from $95.0 million recorded in FY2023.
  • UroGen Pharma's Cash & Equivalents' 5-year high stood at $172.0 million during FY2024, with a 5-year trough of $44.4 million in FY2021.
  • Its 3-year average for Cash & Equivalents is $107.5 million, with a median of $95.0 million in 2023.
  • In the last 5 years, UroGen Pharma's Cash & Equivalents decreased by 16.09% in 2021 and then soared by 81.04% in 2024.
  • Over the past 5 years, UroGen Pharma's Cash & Equivalents (Yearly) stood at $52.9 million in 2020, then fell by 16.09% to $44.4 million in 2021, then climbed by 24.91% to $55.4 million in 2022, then skyrocketed by 71.46% to $95.0 million in 2023, then spiked by 81.04% to $172.0 million in 2024.